字节加码AI for Science，全网悬赏100位科学家！已孵化一家AI制药
Merged summary
TL;DR - ByteDance Seed launched a six-month program to recruit 100 scientists for AI-for-science collaborations, while expanding its work in computational biology and AI-driven drug discovery. Its efforts have already produced multiple protein and molecular models and an AI-pharma company, Anew Therapeutics.
- The program targets doctoral-level researchers in mathematics, physics, chemistry, biology, materials, and engineering who actively use AI and preferably can program.
- Seed has released models including PXDesign, Protenix, SeedProteo, SeedFold, and UniMoMo for protein computation, design, and molecular generation.
- Anew Therapeutics disclosed a preclinical IL-17 small-molecule inhibitor discovered using AI-based virtual screening and molecular generation.
- ByteDance is also applying AI to battery research through a joint laboratory with BYD and has explored mathematical reasoning through IMO 2025 participation.
Sources (1)
字节加码AI for Science，全网悬赏100位科学家！已孵化一家AI制药
TL;DR - ByteDance Seed launched a six-month program to recruit 100 scientists for AI-for-science collaborations, while expanding its work in computational biology and AI-driven drug discovery. Its efforts have already produced multiple protein and molecular models and an AI-pharma company, Anew Therapeutics.
- The program targets doctoral-level researchers in mathematics, physics, chemistry, biology, materials, and engineering who actively use AI and preferably can program.
- Seed has released models including PXDesign, Protenix, SeedProteo, SeedFold, and UniMoMo for protein computation, design, and molecular generation.
- Anew Therapeutics disclosed a preclinical IL-17 small-molecule inhibitor discovered using AI-based virtual screening and molecular generation.
- ByteDance is also applying AI to battery research through a joint laboratory with BYD and has explored mathematical reasoning through IMO 2025 participation.